A bacterial protease inhibitor protects antigens delivered in oral vaccines from digestion while triggering specific mucosal immune responses-Reference-Cited by-同舟云学术

A bacterial protease inhibitor protects antigens delivered in oral vaccines from digestion while triggering specific mucosal immune responses

Published:2015-12 Issue: Volume:220 Page:18-28
ISSN:0168-3659
Container-title:Journal of Controlled Release
language:en
Short-container-title:Journal of Controlled Release

Author:

Ibañez Andrés Esteban,Coria Lorena Mirta,Carabajal Marianela Verónica,Delpino María Victoria,Risso Gabriela Sofía,Cobiello Paula Gonzalez,Rinaldi Jimena,Barrionuevo Paula,Bruno Laura,Frank Fernanda,Klinke Sebastián,Goldbaum Fernando Alberto,Briones Gabriel,Giambartolomei Guillermo Hernán,Pasquevich Karina Alejandra,Cassataro Juliana

Funder

Bill and Melinda Gates Foundation

Agencia Nacional de Promoción Científica y Tecnológica

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference40 articles.

1. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens?;Belyakov;J. Immunol.,2009

2. Delivery strategies to enhance oral vaccination against enteric infections;Davitt;Adv. Drug Deliv. Rev.,2015

3. Vaccine adjuvants: putting innate immunity to work;Coffman;Immunity,2010

4. Mucosal adjuvants;Freytag;Vaccine,2005

5. Oral cholera vaccines: use in clinical practice;Hill;Lancet Infect. Dis.,2006

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perforation of the terminal ileum caused by brucellosis: A case report;Clinical Case Reports;2024-02

2. Oral Nanovaccines Delivery for Clinical Trials and Commercialization;Nanovaccinology as Targeted Therapeutics;2022-06-15

3. A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice;Frontiers in Immunology;2022-02-28

4. A disordered region retains the full protease inhibitor activity and the capacity to induce CD8+ T cells in vivo of the oral vaccine adjuvant U-Omp19;Computational and Structural Biotechnology Journal;2022

5. A novel bacterial protease inhibitor adjuvant in RBD-based COVID-19 vaccine formulations increases neutralizing antibodies, specific germinal center B cells and confers protection against SARS-CoV-2 infection;2021-12-09